A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals

Simply Wall St.

02/19

Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month. ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612428735"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612428735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612428735?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-19 01:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612428735","market":"us","top_or_hot":-1,"title":"A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals","media":"Simply Wall St.","content":"<div>\n<p>Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-19 01:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent","article_id":"2612428735","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612428735","pubTimestamp":1771435684,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month.\nSee our latest analysis for Ionis Pharmaceuticals.\nAlthough the 1 day share price return of 0.94% and recent 7 day weakness suggest some hesitation, Ionis Pharmaceuticals still carries positive momentum, with a 30 day share price return of 6.59% and a 1 year total shareholder return of 154.65%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"在近期股价走强和分析师信号好坏参半后审视Ionis Pharmaceuticals(IONS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1.5},"content_text":"Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month. See our latest analysis for Ionis Pharmaceuticals. Although the 1 day share price return of 0.94% and recent 7 day weakness suggest some hesitation, Ionis Pharmaceuticals still carries positive momentum, with a 30 day share price return of 6.59% and a 1 year total shareholder return of 154.65% reinforcing a stronger longer term picture. If this kind of move in a biotech name has you thinking about where else growth stories might emerge, it could be a good moment to scan 25 healthcare AI stocks for other healthcare names tied to AI driven treatments and tools. With Ionis now trading around US$81, an intrinsic value estimate suggesting roughly 70% upside, and analyst targets sitting near US$91, the key question is whether the market is leaving a margin of safety or already pricing in future growth. AdvertisementMost Popular Narrative: 10.3% Undervalued With Ionis Pharmaceuticals last closing at $81.36 versus a narrative fair value of about $90.67, the widely followed model points to a valuation gap built on specific growth, margin and discount rate assumptions.  The analysts have a consensus price target of $68.346 for Ionis Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $43.0.  Read the complete narrative. Curious why the popular fair value sits above the consensus target? The narrative leans on stronger revenue compounding, a richer profit margin profile and a higher future earnings multiple than many would expect. Result: Fair Value of $90.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the fair value story could be knocked off course if key late stage approvals slip, or if pricing and reimbursement push back as Ionis targets larger populations. Find out about the key risks to this Ionis Pharmaceuticals narrative. Another View: Sales Multiple Sends A Different Signal While our fair value narrative points to Ionis Pharmaceuticals trading at a discount, the current P/S ratio of 13.6x looks punchy next to the US Biotechs industry at 11.3x, peers at 4.8x, and a fair ratio of 5.1x that the market could potentially move toward. If the share price eventually gravitates closer to that 5.1x fair ratio rather than staying at 13.6x, the path for investors may feel very different to the story implied by the narrative fair value. Which signal do you put more weight on? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:IONS P/S Ratio as at Feb 2026Next Steps If this mix of signals leaves you unsure, now is a good time to look through the data yourself, weigh both sides and decide how comfortable you are with the trade off between 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Ionis has you thinking more broadly about your portfolio, it is worth widening the lens and seeing what other opportunities the data is already highlighting for you.  Target potential value opportunities by scanning 56 high quality undervalued stocks to find companies that pair stronger fundamentals with prices that may not fully reflect underlying strength yet. Build a steadier income base by reviewing 13 dividend fortresses for companies offering higher yields that could complement growth oriented positions. Strengthen your downside protection by checking 80 resilient stocks with low risk scores for companies with lower risk scores collected into one practical starting list.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}